A lab technician inspects filled vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir at a Gilead Sciences facility in La Verne, California, U.S. March 11, 2020. Picture taken March 11, 2020.
Gilead Sciences Inc | Reuters
Gilead Sciences published new data Friday on its antiviral drug remdesivir that shows it reduced the risk of death for coronavirus patients by 62% compared with standard care alone.
The findings are being presented at the Virtual Covid-19 Conference as part of the 23rd International AIDS Conference, the company said.
This is breaking news. Please check back for updates.